NASHVILLE, Tenn.—Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced the completion of the transfer to Harrow of the New Drug Application (NDA) for Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy. As reported by VMAIL in January of 2023, Harrow agreed to acquire the U.S. commercial rights to Triesence. Aside from the transfer of the Triesence NDA ahead of the date previously agreed to, all other acquisition terms remain unchanged.

“While we continue to diligently work with our contract manufacturing partner, making solid progress manufacturing commercial batches of Triesence, the mutual agreement to an early transfer of the Triesence NDA was an important step in advancing our strategy to relaunch the product under the Harrow umbrella,” said Mark L. Baum, chief executive officer of Harrow.

“With this crucial process completed, our team has begun to implement our market access, marketing, inventory management, national sales detailing and other brand-leveraging strategies so that we will be ready to relaunch Triesence in the U.S. once we have achieved a successful inventory build, which we are currently working diligently toward. We remain excited to be able to provide Triesence to the U.S. ophthalmic community soon.”